Published:
April 30, 2020
Services:
Chemicals More...
Priorities:
“Better-for-You” Transformation More...
Topics:
Alternative Ingredients | Alternative Proteins More...
Activities:
Markets More...
Further Reading
Global Bioenergies to launch its own range of cosmetic products
News Commentary | April 29, 2021
Global Bioenergies has been shifting its focus to high‑margin applications in recent years. The biotech startup now plans to produce and market a line of makeup products using its own bio‑based ingredient. It will initially produce 300,000 units and aims to have its commercial launch in the next six... Not part of subscription
DMC partners with Conagen for commercial production of L-alanine
News Commentary | May 21, 2021
This announcement follows the company's recent effort to demonstrate the large‑scale production of L‑alanine through 85 m3 fermentation at EW Biotech in Germany. In April 2021, the company also struck a deal with SCG to bring L‑alanine and other branched‑chain amino acids to the ASEAN market. ... Not part of subscription
Suntory's partnership with Anellotech finally reaches a breakthrough, introducing 100% plant-based PET bottle prototypes in Europe and Japan
News Commentary | December 14, 2021
After 10 years and more than $30 million, Suntory finally launched its 100% biobased polyethylene terephthalate (bio‑PET) bottle prototype. This announcement came only weeks after Coca‑Cola announced its version, highlighting the trend in bio‑PET. Suntory’s prototype is made using Anellotech's Bio‑... Not part of subscription
by Harini Venkataraman
Amyris initially launched its Reb M sweetener Purecane in December 2019 in the U.S., and the B2C product is currently sold through Purecane's e-commerce site as well as on Amazon. Following this regulatory approval, Amyris can expand to other countries like Canada and Brazil. Amyris produces its Reb M product by fermentation of cane sugar using an engineered S. cerevisiae production strain. The company previously announced an agreement with Raízen and is in the midst of building a commercial facility for Purecane in Brazil. While Amyris' commercialization through a B2C route provides the company a head start compared to DSM-Cargill's JV Avansya, widespread adoption of Purecane in the B2B sugar reduction market will be key to its success.
For the original news article, click here .